CEPT Inhibitors Finally Show Potential With Obicetrapib

After many setbacks, the potential for CETP inhibition to significantly improve cholesterol levels and target attainment has been shown with obicetrapib in the ROSE trial.

Related Keywords

Milan ,Lombardia ,Italy ,Chicago ,Illinois ,United States ,London ,City Of ,United Kingdom ,Amsterdam ,Noord Holland ,Netherlands ,Albericol Catapano , ,Amgen ,Imperial College London ,Imperial Centre For Cardiovascular Disease Prevention ,European Atherosclerosis Society ,University Of Milan ,Medscape Cardiology ,New Amsterdam Pharma ,Imperial Centre ,Cardiovascular Disease Prevention ,Lipids ,Ipid Management ,Low Ldl Cholesterol ,Ypobetalipoproteinemia ,Ow Low Density Lipoprotein Cholesterol ,Cv ,Ardiovascular ,Dyslipidemia ,Hyperlipidemia ,Cetp Inhibitors ,Holesterylester Transfer Protein Inhibitors ,United Kingdom Site Content ,